Information Not Explicitly Provided
Visit Investigator ProfileInvestigation Details
Detailed Analysis
The investigator takes a meticulous approach to evaluating the compounding processes and ingredients used in drug products. They prioritize assessing compliance with section 503A and section 502(f)(1) of the FDCA, focusing on CGMP compliance and directions for use.
The FDA investigator ''Information Not Explicitly Provided'' has a strong focus on the compounding of drug products and ensuring compliance with section 503A and section 502(f)(1) of the FDCA. They prioritize assessing CGMP compliance and evaluating the adequacy of directions for use.
Unlock Insights from 483s & Stay Audit Ready with FDA Tracker
Monitor FDA Six Systems, Analyse 483s with Observations, Investigators & Companies